Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229390 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL428322 | 0.95 | CHRNB2 (0.49) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL30174297 | 0.95 | CHRNB2 (0.49) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL13779692 | 0.89 | CHRNB2 (0.45) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL21465056 | 0.86 | CHRNB2 (0.48) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL16943508 | 0.83 | APP (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL12104621 | 0.81 | CHRNB2 (0.44) | CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL20126670 | 0.81 | CHRNB2 (0.44) | CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL4364410 | 0.80 | KDM4E (0.41) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL19668758 | 0.80 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
| EP-3294714-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2023-03-15 | — | — | EP | disclosed |
| US-10766864-B2 | Morphinan derivatives for the treatment of neuropathic pain | NEKTAR THERAPEUTICS (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766864-B2 | Morphinan derivatives for the treatment of neuropathic pain | NEKTAR THERAPEUTICS (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180127375-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS | 2018-05-10 | — | — | US | disclosed |
| US-20180127375-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS | 2018-05-10 | — | — | US | disclosed |
| EP-3294714-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | Nektar Therapeutics (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016182840-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016182840-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766864-B2 | Morphinan derivatives for the treatment of neuropathic pain | OPRM1, OPRL1, OPRK1 | CHRNB2 182/4885CHRNA4 120/4885NPC1 2288/4885 |
| US-20180127375-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | OPRM1, OPRL1, OPRK1 | CHRNB2 182/4885CHRNA4 120/4885NPC1 2288/4885 |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | CHRNB2 4468/4885CHRNA4 4400/4885NPC1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.